Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Gilead Sciences strikes partnerships with Scholar Rock and Agenus
by Ryan Cross
January 7, 2019
| A version of this story appeared in
Volume 97, Issue 1
Gilead Sciences formed two partnerships in the final weeks of 2018. The firm is collaborating with Scholar Rock to develop antibodies that inhibit transforming growth factor (TGF) to treat fibrotic diseases. Scholar Rock will earn $80 million up front and up to $1.45 billion more depending on the success of three TGF programs. Separately, Gilead is paying Agenus $150 million to develop up to five cancer immunotherapies, including two bispecific antibodies. Agenus could earn up to $1.7 billion in milestones.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter